Q2i is a digital health company dedicated to developing, refining, validating, and commercializing innovative, evidence-based solutions.
Q2i’s Business Divisions

Science, Research, and Evidence Base
In conjunction with the National Institutes of Health, and collaboration with various academic partners Q2i designs, develops, refines, tests, and empirically measures its technology’s efficacy in impacting and improving target outcomes.

Contingency Management
More organizations rely on Q2i’s CMI Technology to address and overcome the burdens, barriers, and challenges of implementing and managing CM and improve CM programs’ accuracy, immediacy, fidelity, security, and success than all our competitors combined.

Criminal Justice Solutions
Q2i’s patented “PARCA” technology developed through funding and oversight by the National Institutes of Health works to help improve the success of probation and parole/community supervision, reducing recidivism, rearrests, and reincarcerations.
News:
Q2i Reports Significant Milestone in California’s Statewide Contingency Management Program for Stimulant Use Treatment
11 March, 2025 | Read more ›
Q2i, King's College London, and UK Government Join Forces to Revolutionize Prisoner Reintegration with AI
24 Feb, 2025 | Read more ›
Q2i's PARCA Technology Moves to Phase II of National Institutes of Health (NIH) Clinical Trial to Further Evaluate Its Efficacy in Increasing Community Supervision Success
22 Jan, 2025 | Read more ›
Reviews